Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) headquartered in Nashville, will host a conference call for the investment community to discuss the 3Q20 financial results on 10th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.cumberlandpharma.com
Earnings Expectation
Cumberland Pharmaceuticals Inc. is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.07 per share from revenue of $ 8.61 million. Looking ahead, the full year income are expected at $ 0.09 per share on the revenues of $ 38.28 million.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The companys Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.
